Among patients with prior cardiovascular disease, the increased 3‐point MACE risk associated with high‐affinity sulfonylureas was attenuated and not statistically significant compared with DPP‐4 inhibitors (HR, 1.07; 95% CI, 0.98–1.17). Here, DPP4 is linked to cardiovascular disorder.